Jan 23, 2019 It won't be long before this transformation creates many multibaggers in the stock market. As a result, the benefits of shifting to a tax free zone was negated. Most of the Indian pharma companies have been working on these. We are globally recognised as a leader in cyber security. The top five companies were homegrown; Indian firms account for 72% of the bio-pharma sector and 52% of the industry as a whole. The average life expectancy of Indians has risen from 58 years in 1990 to 66 years in 2013. The industry has expanded at a very fast rate to become the second largest producer of textile and garments.
Others invested the money to bring their facilities to compliance, but these operations were located in non-tax-free states, making it difficult to compete in the wake of the new excise tax. Various industry reports suggest that the pharmaceutical sector in India has been growing consistently at the rate of 13-14 % every year since the last five years. Some multinational companies such as Pfizer and Novartis are already taking advantage of the potential in India through partially or wholly owned subsidiaries. With 71 per cent market share, generic drugs form the largest segment of the Indian pharmaceutical sector. Lastly, many multinational companies have also followed a differential price strategy to strengthen their presence in India through availability and affordability of products McKinsey, 2014. This plan included a proposal to create a National Task Force that will work with the biotech industry to revise the curriculum for undergraduate and graduate study in life sciences and biotechnology. The manufactures will be competing in terms of ground and increase in complexity, additional controls and market disruptions in the global supply.
In terms of composition of exports, share of basic drugs was 43%, fine chemicals and intermediates captured 55% of share and 2% of herbals were exported from India McKinsey, 2014. Whilst the multinationals streamed out, Indian companies carved a niche in both the Indian and world markets with their expertise in reverse-engineering new processes for manufacturing drugs at low costs. Global pharma looks to India : Prospects for growth. Consolidation: For the first time in many years, the international pharmaceutical industry is finding great opportunities in India. The biotechnology sector faces some major challenges in its quest for growth. Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved cost-beneficial chemical synthesis for various drug molecules is excellent. During April — September 2017, India exported pharmaceutical products worth Rs 411.
It is one of the major contributors in the healthcare industry. We are trying to make our products available in these small towns. The growth in 2017 stood at 10% over the same period last year. Copyright © Equitymaster Agora Research Private Limited. Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
Meanwhile, Indian firms have chosen to take their existing product portfolios and target semi-urban and rural populations. In addition, the thrust on rural health programme, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies. It is an extremely fragmented market with severe price competition and government price control. June 2016 Indian companies are also starting to adapt their product development processes to the new environment. Apart from this, she has developed keen interest in business management, business policy, international marketing and strategic management. The demand is driven by active participation of pharmaceutical chemicals. In Jul-Sep 2018, Indian pharmaceutical market grew 9.
Unsourced material may be challenged and. It was found that only 11 samples or 0. There is already an established international industry and business community. The Indian biotech market is dominated by biopharmaceuticals; 76% of 2004—5 revenues came from biopharmaceuticals, which saw 30% growth last year. The Indian pharmaceutical industry also needs to take advantage of the recent advances in biotechnology and information technology. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. The Pharmaceutical Industry, with its rich scientific talents and research capabilities, supported by Intellectual Property Protection regime is well set to take on the international market.
However, those that can afford it have set their sights on an even higher goal: new molecule discovery. Generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years. Even though growth has slowed down recently in the event of and demonetisation we believe it will be in the top 10 global markets by 2020. Not marred by recession or inflation, the pharma sector has a competitive advantage of prospering steadily and thus attracts lots of young professionals looking at pharmaceutical as their prospective career option. In addition to this, demand drivers include the growing and ageing global population.
This approach remains untouched by the new patent regime and looks to increase in the future. Most Popular Jan 24, 2019 This irreversible trend has the potential to create the biggest wealth creation opportunity in the next few years. Introduction India is the largest provider of generic drugs globally. Please update this article to reflect recent events or newly available information. India enjoys an important position in the global pharmaceuticals sector. As a condition to accessing Equitymaster content and website, you agree to our. A combination of regulatory, market, scientific, and technological forces is likely to mean that pharmaceuticals manufacturing and supply chain process will undergo rapid change in the near future.
The market is dominated majorly by branded generics, which constitutes nearly 70% of the overall market. At last count there were 265 firms registered in India, over 92% of which were incorporated in the last five years. Characteristics of Indian Pharmaceutical Industry The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. The highest growth was for Mankind Pharma 37. Bio-pharma was the biggest contributor generating 60 percent of the industry's growth at Rs. Alarming rise in cases of cardiovascular problems, nervous system disorders, diabetes and many other diseases as well as disorders has created more awareness in the growing population about the need of improvement in medical sector. Foreign Direct Investment in Indian Pharmaceutical Industry.
The government has laid down tight rules governing the development and production of medicines. India has an organized pharmaceutical market of its own, which is being considered as a potential partner by other countries. Jan 17, 2019 It may not just create tremendous stock market wealth, but also push several Indian companies in the reckoning of global leaders. The performance data quoted represents past performance and does not guarantee future results. The industry has displayed a high rate of growth through improved technology, range and the quality of products manufactured. The currencies of major countries witnessed sharp depreciation, leading to poor realisations. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share.